Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions
Macular Degeneration
Interventions
DRUG

Microplasmin

Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.

DRUG

Placebo control

The placebo control will be the microplasmin vehicle without the microplasmin.

Trial Locations (1)

90095

RECRUITING

Jules Stein Eye Institute/UCLA, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ThromboGenics

INDUSTRY

lead

University of California, Los Angeles

OTHER